Latest news with #Pathway
Irish Examiner
26-05-2025
- Sport
- Irish Examiner
Devine, Treacy and West sign first professional contracts with Connacht
Connacht Rugby announce that John Devine, Finn Treacy and Harry West have signed their first professional contracts with the province ahead of the 2025/26 season. Exclusively announced during the Connacht Rugby Awards on Saturday night, the trio have come up through the Academy pathway system and now move into the pro team setup. Devine will join his brother Matthew as the latest pair of homegrown brothers in the Connacht professional ranks, has excelled for both Corinthians and the Connacht Eagles at inside centre. West came through the club system at Ballina RFC, started out at fly-half before transitioning towardsd full-back. Treacy, winner of Academy Player of the Year, has been drafted from Year two of the Academy after becoming a regular member of the senior matchday squad for the second half of this season. He has made eight appearances to date -starting seven - and has scored five tries to date. The trio have experience at Ireland U20s level. In 2023 Devine started all 10 games for Ireland in the U20s Six Nations and World Championships while West featured in five games as well as the previous U20s Summer Series. In 2024 Treacy made nine appearances across the Six Nations and World Championships. Connacht Academy manager Eric Elwood said 'Today is a proud day for John, Finn and Harry, as well as their families and respective clubs and schools. All three men have worked tremendously hard to get to where they are, and I know they have what is required to take the next step in their careers. "I want to thank everyone involved in their rugby development at their clubs and schools, who helped them on the start of their journey. I also want to acknowledge the coaches and wider Academy staff for the support provided to all our Academy and Pathway players in the season just gone. "Our integration model with the Professional team has provided our up-and-coming players with increased exposure to an elite playing environment, and we will continue to give Academy players the best opportunity possible to grow and develop.' 'Today is a proud day for John, Finn and Harry, as well as their families and respective clubs and schools. All three men have worked tremendously hard to get to where they are, and I know they have what is required to take the next step in their careers. I want to thank everyone involved in their rugby development at their clubs and schools, who helped them on the start of their journey. I also want to acknowledge the coaches and wider Academy staff for the support provided to all our Academy and Pathway players in the season just gone. Our integration model with the Professional team has provided our up-and-coming players with increased exposure to an elite playing environment, and we will continue to give Academy players the best opportunity possible to grow and develop.'
Business Wire
14-05-2025
- Health
- Business Wire
Pathway Expands Medical AI Platform with Drug Reference and Interaction Checker
MONTREAL--(BUSINESS WIRE)-- Pathway today announced the launch of a fully integrated drug reference and drug-drug interaction checker within its AI-powered medical knowledge platform. Clinicians can now access comprehensive medication information for over 2,000 drugs and screen for interactions directly within the same interface they already use for clinical guidance. Built on Pathway's proprietary AI-first drug database, clinicians can now check interactions and access trusted dosing guidance in seconds within the Pathway platform. Share Pathway's drug reference is powered by a proprietary database that is uniquely structured to support AI-native use. It enables consistent, context-aware access to medication data across thousands of clinical scenarios. This foundation is further complemented by trusted sources like the American Hospital Formulary Service (AHFS), a gold-standard reference maintained by the American Society of Health-System Pharmacists (ASHP) and widely used by clinicians and institutions across the United States. Together, this combined data supports clinically relevant and responsible integration within the Pathway platform. 'Clinicians face constant time pressure and information overload,' said Dr. Louis Mullie, Chief Medical Officer at Pathway. 'We built this to keep prescribing information within the flow of care. Medication errors affect over a million patients annually in the U.S., often due to incomplete information or workflow disruptions. By enabling instant access to full monographs and interaction guidance within the Pathway AI experience, we help clinicians make safer and faster decisions without disrupting their workflow.' Clinicians can now ask drug-related questions in plain language through Pathway AI, such as 'What is the dose of pregabalin for postherpetic neuralgia?' or 'What is the dose of bupropion for depression in a patient with liver cirrhosis?', and receive clear, structured answers in seconds. Pathway's new interaction checker also enables quick screening for potential conflicts between medications without needing to switch tools or interrupt patient care. 'At Mee Memorial, Pathway has become an essential part of how we deliver care,' said Dr. Noah Hawthorne, MPH, Chief Medical Officer at Mee Memorial Healthcare System. 'More than half of our searches involve drug information. Pathway's integrated medication database consistently delivers reliable, fast answers, whether for routine prescriptions or complex, patient-specific decisions.' This achievement highlights Pathway's continued leadership at the intersection of AI and clinical decision support. In 2024, the platform became the first generative AI tool in medicine to offer continuing medical education (CME) credit for every question asked, embedding ongoing education into everyday use. In March 2025, the company also introduced HIPAA-compliant access for Pathway Plus subscribers, supporting secure and compliant use of patient-specific information in AI queries. Earlier this month, Pathway's proprietary 'Deep' model achieved the highest score ever reported for any publicly available specialized medical AI. About Pathway Pathway is one of the most widely used AI-powered medical platforms, designed to support real-time clinical decision-making. It helps clinicians work more efficiently, reduce burnout, and stay current with evidence-based guidelines and literature. Combining advanced AI with proprietary data and structured medical knowledge, Pathway delivers fast, transparent answers to complex clinical questions. The platform is built for accuracy, safety, and ease of use, and is used by clinicians in over 10,000 care centers across the United States and internationally. To learn more or try Pathway, visit
National Post
14-05-2025
- Health
- National Post
Pathway Expands Medical AI Platform with Drug Reference and Interaction Checker
Article content Clinicians can now access full medication data and interaction checks in seconds Article content Article content MONTREAL — Pathway today announced the launch of a fully integrated drug reference and drug-drug interaction checker within its AI-powered medical knowledge platform. Clinicians can now access comprehensive medication information for over 2,000 drugs and screen for interactions directly within the same interface they already use for clinical guidance. Article content Built on Pathway's proprietary AI-first drug database, clinicians can now check interactions and access trusted dosing guidance in seconds within the Pathway platform. Article content Pathway's drug reference is powered by a proprietary database that is uniquely structured to support AI-native use. It enables consistent, context-aware access to medication data across thousands of clinical scenarios. This foundation is further complemented by trusted sources like the American Hospital Formulary Service (AHFS), a gold-standard reference maintained by the American Society of Health-System Pharmacists (ASHP) and widely used by clinicians and institutions across the United States. Together, this combined data supports clinically relevant and responsible integration within the Pathway platform. Article content 'Clinicians face constant time pressure and information overload,' said Dr. Louis Mullie, Chief Medical Officer at Pathway. 'We built this to keep prescribing information within the flow of care. Medication errors affect over a million patients annually in the U.S., often due to incomplete information or workflow disruptions. By enabling instant access to full monographs and interaction guidance within the Pathway AI experience, we help clinicians make safer and faster decisions without disrupting their workflow.' Article content Clinicians can now ask drug-related questions in plain language through Pathway AI, such as 'What is the dose of pregabalin for postherpetic neuralgia?' or 'What is the dose of bupropion for depression in a patient with liver cirrhosis?', and receive clear, structured answers in seconds. Pathway's new interaction checker also enables quick screening for potential conflicts between medications without needing to switch tools or interrupt patient care. Article content 'At Mee Memorial, Pathway has become an essential part of how we deliver care,' said Dr. Noah Hawthorne, MPH, Chief Medical Officer at Mee Memorial Healthcare System. 'More than half of our searches involve drug information. Pathway's integrated medication database consistently delivers reliable, fast answers, whether for routine prescriptions or complex, patient-specific decisions.' Article content This achievement highlights Pathway's continued leadership at the intersection of AI and clinical decision support. In 2024, the platform became the first generative AI tool in medicine to offer continuing medical education (CME) credit for every question asked, embedding ongoing education into everyday use. In March 2025, the company also introduced HIPAA-compliant access for Pathway Plus subscribers, supporting secure and compliant use of patient-specific information in AI queries. Earlier this month, Pathway's proprietary 'Deep' model achieved the highest score ever reported for any publicly available specialized medical AI. Article content Pathway is one of the most widely used AI-powered medical platforms, designed to support real-time clinical decision-making. It helps clinicians work more efficiently, reduce burnout, and stay current with evidence-based guidelines and literature. Combining advanced AI with proprietary data and structured medical knowledge, Pathway delivers fast, transparent answers to complex clinical questions. The platform is built for accuracy, safety, and ease of use, and is used by clinicians in over 10,000 care centers across the United States and internationally. Article content Article content Article content Article content Article content
NZ Herald
13-05-2025
- Sport
- NZ Herald
Gisborne clubbies named in NZ surf lifesaving teams for international competitions
The Junior Black Fins squad includes Midway's Jacqueline Kennedy and Ella Sutton. The Pathway team feature Midway's Tyron Evans and Sophie Petro, Waikanae's Seven Mapu and former Wainui and Waikanae athlete Jack Keepa, who now competes for Omanu in the Bay of Plenty. Surf Life Saving NZ (SLNZ) has also announced a youth squad and two other Pathway teams to compete in the Battle of the Tasman on the Gold Coast from August 28 to 30. Sutton is in the Youth team; the White Pathway team includes Petro and clubmate Jack Lepper; and the Grey Pathway team includes Midway's Yahni Brown and Evans. 'The Black Fins boast a rich legacy of success, including multiple world championships and consistent top-two finishes at the International Surf Rescue Challenge since its inception in 1937,' SLSNZ high performance sport manager Tanya Hamilton said. She highlighted the strength of this year's Black Fins squad. 'The wealth of experience within this team will undoubtedly elevate the new talent and place the Black Fins in a strong position to secure victory at the International Surf Rescue Challenge. 'It will be a super-proud moment to see the teams compete in front of a home crowd.' Hamilton said the transtasman event catered for athletes deeper into the performance pathway. 'This competition on the Gold Coast aims to prepare athletes for the Lifesaving World Championship format, the pinnacle event in lifesaving sport. 'It's an exciting year for lifesaving sport, with so many athletes having the chance to compete on the international stage,' Hamilton said. 'Exposure to global competition and the experience of performing under pressure will strengthen our sport and the wider lifesaving movement and keep New Zealand competitive on the world stage.'
Business Wire
02-05-2025
- Business
- Business Wire
Pathway Sets a New Benchmark for Specialty Medical AI with Transparent Just-in-Time Reasoning
MONTREAL--(BUSINESS WIRE)-- Pathway today announced that its proprietary large-language model (LLM) scored 96% on a validated set of United States Medical Licensing Examination (USMLE) questions, the highest accuracy yet reported for a specialized medical AI. The result strengthens Pathway's position as a leading evidence-based decision-support tool for frontline clinicians. Pathway "Deep" achieves 96 % accuracy on the USMLE, the highest publicly reported score for any medical AI model. Share In head-to-head testing, Pathway's 'Deep' AI model surpassed domain-specific peers MediSearch Pro, OpenEvidence and Hippocratic AI, and outperformed generalist systems such as ChatGPT 4o, o1, and GPT-4.5 on complex diagnostic scenarios. Independent academic validation studies are currently underway to further corroborate these groundbreaking results. Pathway attributes the performance to its transparent just-in-time reasoning pipeline, which combines retrieval-augmented generation (RAG) with chain-of-thought (CoT) analysis and agentic tool calling. The architecture allows the model to evaluate multiple information sources simultaneously, surface potential knowledge gaps, generate follow-up questions, and apply clinical scoring and prediction rules—all without adding latency for the user. 'Trust and transparency are foundational for bringing AI into clinical workflows,' said Dr. Louis Mullie, Chief Medical Officer at Pathway. 'Clinicians need speed and accuracy, but they also need verifiable evidence. Pathway's assistant reveals its reasoning step-by-step and links every recommendation to expert-vetted guidelines and a comprehensive drug reference. By giving users the context to double-check dosages and key guidance, Pathway helps them leverage AI efficiently while maintaining full control over patient-safety decisions.' This milestone builds on Pathway's rapid growth and industry recognition. In 2024 Pathway became the first generative-AI medical tool to receive continuing-medical-education (CME) co-accreditation, making every clinical question asked through the platform eligible for CME credit. Earlier this year the company added HIPAA support for Pathway Plus subscribers, enabling secure, compliant integration of patient-specific data into AI queries. Pathway also recently surpassed one million registered users across more than 10,000 healthcare institutions, underscoring its widespread adoption and trust within the medical community. About Pathway Pathway helps clinicians deliver better, faster, safer care by providing instant, evidence-based answers to medical questions. With 1 million+ registered healthcare professionals spanning 10,000 care centers, the AI-powered platform has established a strong presence across the United States and internationally. To learn more or try Pathway, visit
